Wang, Hongying
Wang, Lei
Luan, Huiwen
Xiao, Jing
Zhao, Zhiling
Yu, Pengfei
Deng, Mi
Liu, Yifan
Ji, Shuhao
Ma, Junjie
Zhou, Yan
Zhang, Jiashen
Meng, Xianhui
Zhang, Juan
Zhao, Xinyu
Li, Chunling
Li, Fangmin
Wang, Dapeng
Wei, Shujuan
Hui, Lijun
Nie, Siman
Jin, Changzhu
An, Zhiqiang
Zhang, Ningyan
Wang, Yaopeng
Zhang, Cheng Cheng
Li, Zunling
Funding for this research was provided by:
National Natural Science Foundation of China (82150101, 81872332, 82070225)
University-Enterprise Integration Plan of Yantai (2021XDRHXMQT17)
Leukemia and Lymphoma Society (6629-21)
Welch Foundation (AU-0042-20030616)
Natural Science Foundation of Shandong Province (ZR202103070011, ZR2023QC190)
Article History
Received: 21 April 2024
Accepted: 25 June 2024
First Online: 1 July 2024
Declarations
:
: All patients provided written informed consent. All experiments were approved by the Medical Ethics Committee of Binzhou Medical University (No: 2020–17), and were performed under the national standards of Institutional Animal Care and Use Committee.
: All authors consent to publication.
: CC. Z, Z.A, and N.Z. have patents licensed to, holds equity in, and has Sponsored Research Agreements with Immune-Onc Therapeutics, Inc. Other authors have no competing financial interests.